source
- AstraZeneca says AI has yet to yield clinical candidates but could lower risk in late-stage trialsAstraZeneca's chief executive Pascal Soriot told reporters that the company's AI‑driven efforts in drug design have not yet produced a candidate that has entered clinical testing. He added that th…
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti‑CD122 antibody programArgenx announced a $2.2 billion cash transaction to purchase Forte Biosciences, a biotech focused on autoimmune therapies. The acquisition brings Forte's anti‑CD122 monoclonal antibody, which is c…